Measuring disease progression in primary lateral sclerosis
- PMID: 33602016
- PMCID: PMC7899091
- DOI: 10.1080/21678421.2020.1837179
Measuring disease progression in primary lateral sclerosis
Abstract
Quantitative measures of disease severity are essential outcome measures for clinical trials. The slow progression of disease in primary lateral sclerosis (PLS) requires clinical measures that are sensitive to changes occurring within the time frame of a clinical trial. Proposed clinical outcome measures include the PLS functional rating scale (PLSFRS), burden scores derived from clinical examination findings, and quantitative measures of motor performance. The PLSFRS has good inter-rater reliability and showed greater longitudinal change over 6- and 12-months compared to the revised ALS functional rating scale. Examination-based upper motor neuron burden (UMNB) scales also have good reliability, and longitudinal studies are in process. Quantitative measures of strength, dexterity, gait, and speech have the potential to provide objective and precise measures of clinical change, but have been the least studied in persons with PLS.
Keywords: Primary lateral sclerosis; disease progression; outcome measures.
Conflict of interest statement
Disclosures
The authors have no conflicts of interest to disclose.
Similar articles
-
Longitudinal evaluation of upper motor neuron burden scales in primary lateral sclerosis.Amyotroph Lateral Scler Frontotemporal Degener. 2021 Feb;22(1-2):23-29. doi: 10.1080/21678421.2020.1790609. Epub 2020 Jul 13. Amyotroph Lateral Scler Frontotemporal Degener. 2021. PMID: 32657626 Free PMC article.
-
Structural imaging differences and longitudinal changes in primary lateral sclerosis and amyotrophic lateral sclerosis.Neuroimage Clin. 2012 Dec 24;2:151-60. doi: 10.1016/j.nicl.2012.12.003. eCollection 2012. Neuroimage Clin. 2012. PMID: 24179768 Free PMC article.
-
Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALS.Neurology. 2009 Jun 2;72(22):1948-52. doi: 10.1212/WNL.0b013e3181a8269b. Neurology. 2009. PMID: 19487653
-
Could PLS represent a UMN-predominant ALS syndrome?Rev Neurol (Paris). 2025 Jan-Feb;181(1-2):52-57. doi: 10.1016/j.neurol.2024.04.006. Epub 2024 May 22. Rev Neurol (Paris). 2025. PMID: 38782644 Review.
-
Amyotrophic lateral sclerosis and primary lateral sclerosis: The role of diffusion tensor imaging and other advanced MR-based techniques as objective upper motor neuron markers.Ann N Y Acad Sci. 2005 Dec;1064:61-77. doi: 10.1196/annals.1340.013. Ann N Y Acad Sci. 2005. PMID: 16394148 Review.
Cited by
-
Better understanding the neurobiology of primary lateral sclerosis.Amyotroph Lateral Scler Frontotemporal Degener. 2020 Nov;21(sup1):35-46. doi: 10.1080/21678421.2020.1837175. Amyotroph Lateral Scler Frontotemporal Degener. 2020. PMID: 33602014 Free PMC article. Review.
-
Pseudobulbar affect: clinical associations, social impact and quality of life implications - Lessons from PLS.J Neurol. 2025 Mar 12;272(4):266. doi: 10.1007/s00415-025-12971-y. J Neurol. 2025. PMID: 40072589 Free PMC article.
-
Association between cardiometabolic diseases and the risk and progression of motor neuron diseases in Sweden: a population-based case-control study.Lancet Reg Health Eur. 2024 Dec 10;49:101173. doi: 10.1016/j.lanepe.2024.101173. eCollection 2025 Feb. Lancet Reg Health Eur. 2024. PMID: 39759580 Free PMC article.
-
Variability of the Penn upper motor neuron score in amyotrophic lateral sclerosis: need for a revised score.J Neurol. 2025 Feb 15;272(3):208. doi: 10.1007/s00415-025-12895-7. J Neurol. 2025. PMID: 39954119 Free PMC article.
-
The impact of upper motor neuron involvement on clinical features, disease progression and prognosis in amyotrophic lateral sclerosis.Front Neurol. 2023 Sep 26;14:1249429. doi: 10.3389/fneur.2023.1249429. eCollection 2023. Front Neurol. 2023. PMID: 37822527 Free PMC article.
References
-
- Group AS. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group. Arch Neurol. 1996;53(2):141–147. - PubMed
-
- Gordon PH, Miller RG, Moore DH. ALSFRS-R. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5 Suppl 1:90–93. - PubMed
-
- Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol. 2014;13(11):1127–1138. - PubMed
-
- Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169(1–2):13–21. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous